OBETICHOLIC ACID APPROVED BY FDA FOR RARE LIVER DISEASE

摘要

The US Food and Drug Administration (FDA) has approved Ocaliva (obeticholic acid) for patients with primary biliary cholangitis (PBC). The drug has been approved in combination with ursodeoxycholic acid (UDCA) for the treatment of adults who have had an inadequate response to UDCA alone. The drug can also be used on its own for patients who can't tolerate UDCA, which was the first (and previously only) drug to be approved for the disease in 1997.